No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
PAVMZ Pavmed Inc C/Wts 30/04/2024(To Pur Com) Class Z
- 0.0101
- -0.0049-32.67%
Close Dec 20 16:00 ET
134.77KMarket Cap0.00P/E (TTM)
0.0195High0.0100Low16.38KVolume0.0150Open0.0150Pre Close210.00Turnover0.12%Turnover Ratio0.00P/E (Static)13.34MShares0.180052wk High0.00P/B134.77KFloat Cap0.010052wk Low--Dividend TTM13.34MShs Float8.0700Historical High--Div YieldTTM63.33%Amplitude0.0012Historical Low0.0120Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln
PAVmed Is Maintained at Buy by Ascendiant Capital
PAVmed Analyst Ratings
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21
PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.
Lucid Diagnostics And Subsidiary Of PAVmed Announced That It Has Submitted Its Complete Clinical Evidence Package For Its Esoguard Esophageal DNA Test To Molecular Diagnostics Program Seeking Medicare Coverage For Esoguard Esophageal DNA Test
Heat List
US
Overall
Symbol
Price
% Chg
No Data